Thrivent Financial for Lutherans Has $20.32 Million Stake in argenx SE (NASDAQ:ARGX)

Thrivent Financial for Lutherans lessened its holdings in argenx SE (NASDAQ:ARGX) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,065 shares of the company’s stock after selling 4,287 shares during the period. Thrivent Financial for Lutherans owned approximately 0.05% of argenx worth $20,324,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Victory Capital Management Inc. raised its holdings in argenx by 69.8% during the 3rd quarter. Victory Capital Management Inc. now owns 1,562 shares of the company’s stock valued at $847,000 after acquiring an additional 642 shares during the period. Oppenheimer & Co. Inc. bought a new stake in argenx during the 3rd quarter valued at $453,000. Natixis Advisors LLC raised its holdings in argenx by 13.0% during the 3rd quarter. Natixis Advisors LLC now owns 12,014 shares of the company’s stock valued at $6,513,000 after acquiring an additional 1,379 shares during the period. Advisors Asset Management Inc. raised its holdings in argenx by 15.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 927 shares of the company’s stock valued at $503,000 after acquiring an additional 123 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in argenx by 28.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock valued at $1,875,000 after acquiring an additional 768 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Down 1.1 %

NASDAQ ARGX opened at $613.04 on Friday. The company has a 50-day simple moving average of $635.52 and a two-hundred day simple moving average of $598.47. The firm has a market cap of $37.25 billion, a price-to-earnings ratio of -696.64 and a beta of 0.59. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Equities analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a report on Tuesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Wells Fargo & Company upped their target price on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Finally, Piper Sandler upped their target price on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.